It will be interesting to see how the market digests this. Revenue probably not as high as some may have been expecting, but being it was only the first quarter of operations, and looks like the March quarter will be the start of some juicy revenue contracts signed, some may look at this more so.
It looks like some of the pilot trials are taking longer to sign than anticipated, but the revenue from these deals, once signed, should flow over into this quarter.
I believe they will exceed the recently upgraded revenue target.
Noggie
Read disclaimer below
CRO Price at posting:
7.5¢ Sentiment: Buy Disclosure: Held
